Bill Few Associates Inc. Buys 1,957 Shares of Pfizer Inc. $PFE

Bill Few Associates Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the 2nd quarter, Holdings Channel reports. The fund owned 84,256 shares of the biopharmaceutical company’s stock after acquiring an additional 1,957 shares during the quarter. Bill Few Associates Inc.’s holdings in Pfizer were worth $2,042,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at $27,000. North Capital Inc. bought a new position in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter valued at $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the first quarter valued at $35,000. Finally, WPG Advisers LLC bought a new position in Pfizer in the first quarter valued at $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $24.81 on Monday. The firm has a 50-day moving average of $24.86 and a 200-day moving average of $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.